A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) (NCT05239728)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Has a histologically or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer (AJCC) (8th Edition), with or without sarcomatoid features
2. Has intermediate-high risk, high risk, or M1 no evidence of disease (NED) RCC as defined by the following pathological tumor-node metastasis and tumor grading:
3. Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, any grade, N0, M0
4. High risk RCC: pT4, any Grade N0, M0; pT any stage, any Grade, N+, M0
5. M1 NED RCC participants who present not only with the primary kidney tumor but also solid, isolated, soft tissue metastases that can be completely resected at one of the following: the time of nephrectomy (synchronous) or, ≤2 years from nephrectomy (metachronous)
6. Has undergone complete resection of the primary tumor (partial or radical nephrectomy) and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants
7. Must have undergone a nephrectomy and/or metastasectomy ≤12 weeks prior to randomization
8. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days before randomization.
9. Male participants must agree to continue contraception at least 7 days after the last dose of belzutifan/placebo
10. Female participants of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of pembrolizumab or at least 30 days after last dose of belzutifan/placebo, whichever occurs last
11. Has adequate organ function

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (285 Sites)

• Mayo Clinic in Arizona - Phoenix ( Site 3554) — Phoenix, Arizona
• City of Hope Comprehensive Cancer Center ( Site 3567) — Duarte, California
• Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516) — La Jolla, California
• UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 3520) — Los Angeles, California
• University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3518) — Orange, California
• Stanford Cancer Center ( Site 3523) — Palo Alto, California
• University of Colorado Anschutz Medical Campus ( Site 3514) — Aurora, Colorado
• Intermountain Health St. Mary's Regional Hospital ( Site 3562) — Grand Junction, Colorado
• Georgetown University Medical Center ( Site 3534) — Washington D.C., District of Columbia
• University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 3517) — Miami, Florida
• Moffitt Cancer Center ( Site 3540) — Tampa, Florida
• Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 3515) — Marietta, Georgia
• Parkview Research Center at Parkview Regional Medical Center ( Site 3526) — Fort Wayne, Indiana
• Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center- GU Oncology ( Site 3549) — Baltimore, Maryland
• Massachusetts General Hospital ( Site 3571) — Boston, Massachusetts
• Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 3572) — Boston, Massachusetts
• Dana-Farber Cancer Institute-GU ( Site 3505) — Boston, Massachusetts
• Cancer and Hematology Centers of Western Michigan ( Site 3502) — Grand Rapids, Michigan
• Washington University-Internal Medicine/Oncology ( Site 3531) — St Louis, Missouri
• St. Vincent Frontier Cancer Center-Research ( Site 3506) — Billings, Montana
• Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 3550) — Omaha, Nebraska
• Englewood Hospital and Medical Center ( Site 3557) — Englewood, New Jersey
• Rutgers Cancer Institute of New Jersey ( Site 3541) — New Brunswick, New Jersey
• Monter Cancer Center ( Site 3560) — Lake Success, New York
• Icahn School of Medicine at Mount Sinai ( Site 3539) — New York, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.